Gram-negative bacterial infections
: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group.
(Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application directed to compositions of matter and methods of use of certain 'non-hydroxamate' inhibitors of LpxC for the treatment of Gram-negative bacterial infections
The funding will support the further clinical development of SPR206, Spero's intravenous-administered product candidate from its Potentiator Platform that is being developed as an innovative alternative option to treat MDR Gram-negative bacterial infections
. The award commits non-dilutive funding of $5.9M over a four-year period to cover the costs of select Phase 1 pharmacology studies, a 28-day GLP non-human primate toxicology study, and microbiological surveillance studies that would be required for a potential New Drug Application submission with the U.S.
This is a global problem that requires global action, particularly for the treatment of multi-drug resistant Gram-negative bacterial infections
. Gram-negative bacteria are naturally resistant to many antibiotics used clinically, and have evolved to be resistant towards most other antibiotics following years of treatment with those medicines.
The Superbugs and Superdrugs conference on the 18th-19th March in London, will provide attendees with industry-led insight into current strategies to tackle AMR, novel immunotherapeutics to target Gram-negative bacterial infections
, strategies to combat [sz]-lactamases, precision antibiotics, and more.
glycoprotein-90 and Lumbricin I antibacterial molecules in L.rubellus extract are known highly sensitive to gram-positive bacteria, but it can also work against gram-negative bacterial infections
such as S.typhimurium.
is an emerging biopharmaceutical company focused on the discovery and development of first-in-class lysin-based antimicrobial therapeutics for patients with multi-drug resistant Gram-negative bacterial infections
In India, MDR and XDR Gram-negative bacterial infections
are frequent, and the availability of effective antibiotic therapies are declining.
As in this experimental study, elevated plasma levels of MCP-1 were found in humans with sepsis and septic shock; however, no differences were found between patients with gram-positive and gram-negative bacterial infections
United States-based Pfizer has introduced Zavicefta (ceftazidime/avibactam), a combination antibiotic intended to treat Gram-negative bacterial infections
requiring hospitalisation, in the UK and Germany, it was reported yesterday.
coli is considered the most common isolates in many gram-negative bacterial infections
, and it is mostly susceptible to amikacin.
First FDA-approved in February 2015, AVYCAZ is an antibiotic developed to treat certain Gram-negative bacterial infections
. It consists of ceftazidime, a thirdgeneration cephalosporin, and avibactam, a non-B lactam B-lactamase inhibitor.